Replimune Group, Inc. has received a complete response letter (CRL) from the FDA regarding its Biologics License Application (BLA) for RP1 in combination with nivolumab for advanced melanoma treatment. The company strongly disagrees with the FDA’s assessment, arguing that the data supporting RP1’s efficacy and safety, including a 34% response rate and a median duration of 24.8 months, warrants expedited approval. Replimune’s CEO, Dr. Sushil Patel, emphasized the urgent need for this therapy, as approximately 8,500 Americans die from advanced melanoma each year.

The significance of this development lies in the discrepancies between the FDA’s prior feedback and its current stance. Notably, the FDA had previously indicated that a single-arm trial could be acceptable for accelerated approval if the data were compelling. Replimune’s IGNYTE trial demonstrated a 30.6-month median progression-free survival with RP1 plus nivolumab compared to just 4.4 months with prior PD-1 therapies. Despite these promising results and support from melanoma experts, the FDA’s inconsistent communication and review process have raised concerns about the regulatory landscape for innovative cancer therapies.

The implications of this CRL extend beyond Replimune and RP1, highlighting a critical need for regulatory reform to facilitate timely access to potentially life-saving therapies. The challenges faced by Replimune may prompt a reevaluation of the FDA’s approach to breakthrough therapies, potentially affecting timelines for drug development across the oncology sector. As the company scales back its U.S. operations, the incident underscores the risks that regulatory hurdles pose to innovation in cancer treatment, ultimately impacting patient access to novel therapies.

Source: globenewswire.com